Loss of APAF-1 expression is associated with early recurrence in stage I, II, and III colorectal cancer

[1]  Jun Yu,et al.  MicroRNAs predict and modulate responses to chemotherapy in colorectal cancer , 2015, Cell proliferation.

[2]  Xiaobing Fu,et al.  Elevated microRNA-23a Expression Enhances the Chemoresistance of Colorectal Cancer Cells with Microsatellite Instability to 5-Fluorouracil by Directly Targeting ABCF1. , 2015, Current protein & peptide science.

[3]  M. Lai,et al.  MiR-22 regulates 5-FU sensitivity by inhibiting autophagy and promoting apoptosis in colorectal cancer cells. , 2015, Cancer letters.

[4]  S. Chiou,et al.  Comparison of clinicopathological characteristics and prognosis between early and late recurrence after curative surgery for colorectal cancer. , 2014, American journal of surgery.

[5]  G. Xue,et al.  MicroRNA‐23a Antisense Enhances 5‐Fluorouracil Chemosensitivity Through APAF‐1/Caspase‐9 Apoptotic Pathway in Colorectal Cancer Cells , 2014, Journal of cellular biochemistry.

[6]  F. Giuliante,et al.  Early Recurrence After Liver Resection for Colorectal Metastases: Risk Factors, Prognosis, and Treatment. A LiverMetSurvey-Based Study of 6,025 Patients , 2014, Annals of Surgical Oncology.

[7]  Ming-Feng Hou,et al.  MicroRNA-93 inhibits tumor growth and early relapse of human colorectal cancer by affecting genes involved in the cell cycle. , 2012, Carcinogenesis.

[8]  Tai-Yue Kuo,et al.  Computational Analysis of mRNA Expression Profiles Identifies MicroRNA-29a/c as Predictor of Colorectal Cancer Early Recurrence , 2012, PloS one.

[9]  A. Kwon,et al.  Predictors and outcome of early recurrence after resection of hepatic metastases from colorectal cancer , 2012, Langenbeck's Archives of Surgery.

[10]  Jochen H M Prehn,et al.  Clinical application of a systems model of apoptosis execution for the prediction of colorectal cancer therapy responses and personalisation of therapy , 2011, Gut.

[11]  W. Cho.  MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy. , 2010, The international journal of biochemistry & cell biology.

[12]  M. Aghili,et al.  Clinical and pathological evaluation of patients with early and late recurrence of colorectal cancer , 2010, Asia-Pacific journal of clinical oncology.

[13]  H. Malik,et al.  Predictors of early disease recurrence following hepatic resection for colorectal cancer metastasis. , 2007, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[14]  Ki-Seok Jang,et al.  Reduced Expression of Apaf-1 in Colorectal Adenocarcinoma Correlates with Tumor Progression and Aggressive Phenotype , 2007, Annals of Surgical Oncology.

[15]  Y. Cho,et al.  Clinical and Pathologic Evaluation of Patients with Recurrence of Colorectal Cancer Five or More Years After Curative Resection , 2007, Diseases of the colon and rectum.

[16]  J. Meyerhardt,et al.  Adjuvant Treatment of Colorectal Cancer , 2007, CA: a cancer journal for clinicians.

[17]  J. Jass,et al.  Loss of APAF-1 expression is associated with tumour progression and adverse prognosis in colorectal cancer. , 2007, European journal of cancer.

[18]  K. Shirouzu,et al.  Characteristics of recurrence and surveillance tools after curative resection for colorectal cancer: a multicenter study. , 2007, Surgery.

[19]  M. Hellinger,et al.  Reoperation for recurrent colorectal cancer. , 2006, Clinics in colon and rectal surgery.

[20]  C. Compton,et al.  The predictive value of apoptosis protease‐activating factor 1 in rectal tumors treated with preoperative, high‐dose‐rate brachytherapy , 2006, Cancer.

[21]  A. Baldi,et al.  Role of Apaf‐1, a key regulator of apoptosis, in melanoma progression and chemoresistance , 2005, Experimental dermatology.

[22]  H. Pilch,et al.  Expression of Apaf-1 in cervical cancer correlates with lymph node metastasis but not with intratumoral hypoxia. , 2005, Gynecologic oncology.

[23]  L. Ben-Porat,et al.  Operative Salvage for Locoregional Recurrent Colon Cancer After Curative Resection: An Analysis of 100 Cases , 2005, Diseases of the colon and rectum.

[24]  T. Unek,et al.  Potentially Curative Resection for Locoregional Recurrence of Colorectal Cancer , 2004, Surgery Today.

[25]  M. Martinka,et al.  Reduced Apaf-1 expression in human cutaneous melanomas , 2004, British Journal of Cancer.

[26]  David C. Atkins,et al.  Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Yves Pommier,et al.  Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks , 2004, Oncogene.

[28]  D. Elashoff,et al.  Allelic Imbalance of 12q22–23 Associated with APAF-1 Locus Correlates with Poor Disease Outcome in Cutaneous Melanoma , 2004, Cancer Research.

[29]  G. Botti,et al.  Analysis of APAF‐1 expression in human cutaneous melanoma progression , 2004, Experimental dermatology.

[30]  C. Earle,et al.  Follow-up of patients with curatively resected colorectal cancer: a practice guideline , 2003, BMC Cancer.

[31]  Yoichi Tanaka,et al.  Recurrence patterns after curative resection of colorectal cancer in patients followed for a minimum of ten years. , 2003, Hepato-gastroenterology.

[32]  W. Longo,et al.  The preoperative assessment and postoperative surveillance of patients with colon and rectal cancer. , 2002, The Surgical clinics of North America.